JP2004501964A5 - - Google Patents

Download PDF

Info

Publication number
JP2004501964A5
JP2004501964A5 JP2002506715A JP2002506715A JP2004501964A5 JP 2004501964 A5 JP2004501964 A5 JP 2004501964A5 JP 2002506715 A JP2002506715 A JP 2002506715A JP 2002506715 A JP2002506715 A JP 2002506715A JP 2004501964 A5 JP2004501964 A5 JP 2004501964A5
Authority
JP
Japan
Prior art keywords
methylmalonic acid
agent
chlorocobalamin
acid lowering
lowering drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002506715A
Other languages
English (en)
Japanese (ja)
Other versions
JP5102928B2 (ja
JP2004501964A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/014860 external-priority patent/WO2002002093A2/en
Publication of JP2004501964A publication Critical patent/JP2004501964A/ja
Publication of JP2004501964A5 publication Critical patent/JP2004501964A5/ja
Application granted granted Critical
Publication of JP5102928B2 publication Critical patent/JP5102928B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002506715A 2000-06-30 2001-06-15 新規な葉酸代謝拮抗薬の組み合わせ療法 Expired - Lifetime JP5102928B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US21531000P 2000-06-30 2000-06-30
US60/215,310 2000-06-30
US23585900P 2000-09-27 2000-09-27
US60/235,859 2000-09-27
US28444801P 2001-04-18 2001-04-18
US60/284,448 2001-04-18
PCT/US2001/014860 WO2002002093A2 (en) 2000-06-30 2001-06-15 Combination containing an antifolate and methylmalonic acid lowering agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012144570A Division JP5469706B2 (ja) 2000-06-30 2012-06-27 新規な葉酸代謝拮抗薬の組み合わせ療法

Publications (3)

Publication Number Publication Date
JP2004501964A JP2004501964A (ja) 2004-01-22
JP2004501964A5 true JP2004501964A5 (cg-RX-API-DMAC7.html) 2008-11-20
JP5102928B2 JP5102928B2 (ja) 2012-12-19

Family

ID=27396105

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2002506715A Expired - Lifetime JP5102928B2 (ja) 2000-06-30 2001-06-15 新規な葉酸代謝拮抗薬の組み合わせ療法
JP2012144570A Expired - Lifetime JP5469706B2 (ja) 2000-06-30 2012-06-27 新規な葉酸代謝拮抗薬の組み合わせ療法
JP2013213276A Withdrawn JP2014005304A (ja) 2000-06-30 2013-10-11 新規な葉酸代謝拮抗薬の組み合わせ療法
JP2015087012A Withdrawn JP2015178501A (ja) 2000-06-30 2015-04-21 新規な葉酸代謝拮抗薬の組み合わせ療法
JP2016192173A Withdrawn JP2017019852A (ja) 2000-06-30 2016-09-29 新規な葉酸代謝拮抗薬の組み合わせ療法
JP2018156677A Withdrawn JP2018197265A (ja) 2000-06-30 2018-08-23 新規な葉酸代謝拮抗薬の組み合わせ療法
JP2020072098A Pending JP2020117536A (ja) 2000-06-30 2020-04-14 新規な葉酸代謝拮抗薬の組み合わせ療法

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2012144570A Expired - Lifetime JP5469706B2 (ja) 2000-06-30 2012-06-27 新規な葉酸代謝拮抗薬の組み合わせ療法
JP2013213276A Withdrawn JP2014005304A (ja) 2000-06-30 2013-10-11 新規な葉酸代謝拮抗薬の組み合わせ療法
JP2015087012A Withdrawn JP2015178501A (ja) 2000-06-30 2015-04-21 新規な葉酸代謝拮抗薬の組み合わせ療法
JP2016192173A Withdrawn JP2017019852A (ja) 2000-06-30 2016-09-29 新規な葉酸代謝拮抗薬の組み合わせ療法
JP2018156677A Withdrawn JP2018197265A (ja) 2000-06-30 2018-08-23 新規な葉酸代謝拮抗薬の組み合わせ療法
JP2020072098A Pending JP2020117536A (ja) 2000-06-30 2020-04-14 新規な葉酸代謝拮抗薬の組み合わせ療法

Country Status (11)

Country Link
US (4) US7053065B2 (cg-RX-API-DMAC7.html)
EP (1) EP1313508B1 (cg-RX-API-DMAC7.html)
JP (7) JP5102928B2 (cg-RX-API-DMAC7.html)
AT (1) ATE359823T1 (cg-RX-API-DMAC7.html)
AU (1) AU2001269688A1 (cg-RX-API-DMAC7.html)
CY (1) CY1107649T1 (cg-RX-API-DMAC7.html)
DE (1) DE60127970T2 (cg-RX-API-DMAC7.html)
DK (1) DK1313508T5 (cg-RX-API-DMAC7.html)
ES (1) ES2284660T3 (cg-RX-API-DMAC7.html)
PT (1) PT1313508E (cg-RX-API-DMAC7.html)
WO (1) WO2002002093A2 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1313508B1 (en) * 2000-06-30 2007-04-18 Eli Lilly And Company Combination containing an antifolate and methylmalonic acid lowering agent
DK1874821T3 (da) 2005-04-26 2013-07-08 Trion Pharma Gmbh Kombination af antistoffer med glykokortikoider til behandling af kræft
AU2007204410A1 (en) * 2006-01-12 2007-07-19 Novartis Ag Combination of mTOR inhibitor and antipolate compound
WO2010021843A1 (en) * 2008-08-20 2010-02-25 Eli Lilly And Company Use of antifolates in patients with detectable levels of tff-1 for the cancer treatment
WO2010138955A2 (en) 2009-05-29 2010-12-02 University Of Florida Research Foundation, Inc. Methods and compositions for treating neoplasia
US10736969B2 (en) 2010-12-21 2020-08-11 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
LT2854768T (lt) 2012-05-30 2017-06-12 Fresenius Kabi Oncology Limited Pemetreksedo farmacinės kompozicijos
US10064869B2 (en) 2014-06-04 2018-09-04 Thomas Helledays Stiftelse For Medicinsk Forskning MTH1 inhibitors for treatment of inflammatory and autoimmune conditions
US10531957B2 (en) 2015-05-21 2020-01-14 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
AU2016298439B2 (en) * 2015-07-30 2018-11-08 Expression Pathology, Inc. Quantifying FR-alpha and GART proteins for optimal cancer therapy
DK3386546T3 (en) * 2015-12-07 2024-11-25 General Oncology Inc Combination for the effective treatment of metastatic cancer in patients
WO2018031968A1 (en) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
CA3177187A1 (en) 2016-08-12 2018-02-15 L.E.A.F Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
EP3565549B1 (en) 2017-01-09 2022-03-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2019157133A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
CA3090381A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated lometrexol and uses thereof
JP7491573B2 (ja) 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化メトトレキセートおよびその使用
EP3749318A4 (en) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES
CN111954531A (zh) 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 α聚谷氨酸化培美曲塞及其用途
CN111954530A (zh) 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 γ聚谷氨酸化培美曲塞及其用途
US12076402B2 (en) 2018-02-07 2024-09-03 L.E.A.F. Holdings Group Llc Alpha polyglutamated antifolates and uses thereof
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
CA3090384A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
US11730738B2 (en) 2018-02-07 2023-08-22 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
CA3090506A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated tetrahydrofolates and uses thereof
US12048766B2 (en) 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
WO2019160734A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
CA3090943A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
US12048767B2 (en) 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
WO2019160733A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated methotrexate and uses thereof
WO2023177894A1 (en) 2022-03-18 2023-09-21 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and an antimetabolite agent
WO2025247952A1 (en) * 2024-05-30 2025-12-04 Université De Fribourg Inhibition of cyanide overproduction for the therapy of down syndrome and nonketotic hyperglycinemia

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US225030A (en) * 1880-03-02 Rotary engine
US216350A (en) * 1879-06-10 Improvement in car-replacers
US2920015A (en) * 1957-08-27 1960-01-05 Armour & Co Long-acting vitamin b12
CH605550A5 (cg-RX-API-DMAC7.html) * 1972-06-08 1978-09-29 Research Corp
US5563126A (en) * 1986-11-20 1996-10-08 Metabolite Laboratories Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
US5405839A (en) * 1989-02-28 1995-04-11 Teijin Limited Vitamin B12 derivative, preparation process thereof, and use thereof
JP2962755B2 (ja) * 1989-02-28 1999-10-12 帝人株式会社 新規ビタミンｂ▲下１▼▲下２▼誘導体、その製造方法並びにその用途
KR0162654B1 (ko) * 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
DK0505640T4 (da) * 1991-03-29 2002-12-16 Lilly Co Eli Forbedret terapeutisk metode
JPH05163160A (ja) * 1991-12-13 1993-06-29 Snow Brand Milk Prod Co Ltd 免疫低下に伴う感染症の予防及び治療用栄養剤
US6207651B1 (en) * 1996-08-02 2001-03-27 Metabolite Laboratories Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
KR100361075B1 (ko) 1994-04-08 2003-04-10 리셉타겐 코포레이션 리셉터조절제및그와관련된방법
AU3972195A (en) * 1994-10-12 1996-05-06 Research & Diagnostics Systems, Inc. Reticulocyte assay control
EP1313508B1 (en) * 2000-06-30 2007-04-18 Eli Lilly And Company Combination containing an antifolate and methylmalonic acid lowering agent
US20040005311A1 (en) * 2001-07-20 2004-01-08 Pitman Bradford D. Dietary supplement compositions

Similar Documents

Publication Publication Date Title
JP2004501964A5 (cg-RX-API-DMAC7.html)
LU92323I2 (fr) La combinaison de (a) dextromethorphan ou un de ses sels pharmaceutiquement acceptables, précursers ou dérivés, par ex. hydrobromure de dextromethorphan et en particulier hydrobromure de dextromethorphan monohydrate;et (b) quinidine ou un de ses selspharmacuetiquement acceptables, précurseurs ou dé rivés, par ex. sulfate de quinidine et en particulier sulfate de quinidine dihydrate
AP2004003120A0 (en) Combined use of antitumor indolopyrrolocarbazole derivatives and other antitumor agent
BR0314236A (pt) Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
WO2002043765A3 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
JP2003501474A5 (cg-RX-API-DMAC7.html)
CA2455774A1 (en) Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain
KR920007629A (ko) SALMe염, 5-MTHF 및 5-FTHF 중에서 선택된 화합물 적어도 1개를 유효성분으로서 함유하여 AIDS환자의 신경학적 질환치료시 활성을 나타내는 약제학적 조성물
AR033444A1 (es) Forma solida de dosificacion util para la administracion oral de un compuesto activo de nicotina, a traves de la mucosa y uso de un compuesto activo de nicotina para prepararla
CA2098738A1 (en) Controlled Release Oxycodone Compositions
RU2002127804A (ru) Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения
JP2004503598A5 (cg-RX-API-DMAC7.html)
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
IL158155A (en) Use of erythropoietin for the preparation of a medicament to ameliorate chemotherapy-induced toxicity
ATE466008T1 (de) P-glycoprotein-inhibitor, verfahren zu dessen herstellung und pharmazeutische zusammensetzung, die diesen enthält
KR900005978A (ko) 키니딘, 아르테미시닌 및 이의 유도체를 사용한 항말라리아 조성물 및 치료방법
JP2001513506A5 (cg-RX-API-DMAC7.html)
TNSN05080A1 (en) NOVEL ANTIMYCOBACTERIAL COMPOUNDS (as filed) AND PYRROLE DERIVATIVES AS ANTIMYCOBACTERIAL COMPOUNDS (as published)
KR900701259A (ko) 다가 소염제
NO20010454D0 (no) Anvendelse av derivater av camptotécin med en redusert gastrointestinal toksisitet
CA2503286A1 (en) Compounds for the treatment of tobacco dependence and withdrawal
WO1996011005A3 (en) Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases
WO2005013935A3 (en) Composition for releasing a weak base for an extended period of time
MXPA01012936A (es) Composicion farmaceutica que contiene sibutramina y orlistat.
JPH11508566A (ja) リファブチンを含む抗細菌相乗性組成物